Clinical trial NCT00842283: Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
Official title: Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Dermatologic Diseases
Keywords: dermatologic diseases
Lead sponsor: University of California, Irvine
Sponsor class: OTHER
First posted: 2009-02-12
Enrollment: 85
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Tissue samples will be collected from Dermatopathology Lab, Pathology lab, discarded tissue from dermatologic surgery at University of California Irvine. Additional biopsies may be obtained of known lesions.

Brief summary: The researchers believe that pro-angiogenic factors are upregulated in a wide range of dermatologic diseases, including port wine stains, hemangiomas, angiofibromas, Kaposi's sarcoma, angiosarcoma, scars, rosacea, and psoriasis. Select specimens may undergo genetic analysis to investigate underlying molecular pathways associated with dysregulated angiogenesis in cutaneous disease.

Biospecimens, either previously obtained or newly collected from dermatologic conditions, will be analyzed for angiogenic markers. Discarded skin tissue from surgical or biopsy procedures may also be used, including both diseased and non-diseased tissue from the same donor. Some specimens may also undergo genetic analysis to investigate underlying molecular pathways.

De-identified data such as age, sex, race, cause of death, lesion location, and description will be recorded. Currently, specimens are limited to clinically diagnosed lesions not typically biopsied, or lesions already confirmed by prior biopsy.

Detailed description: Biospecimens from various dermatologic diseases, including port wine stains, hemangiomas, angiofibromas, Kaposi's sarcoma, angiosarcoma, scars, rosacea, and psoriasis will be evaluated for markers of angiogenesis. Additionally, researchers can use discarded human skin tissue samples from skin biopsy/surgery sites, which are removed for closure but are not submitted for histopathologic analysis. We may use donated tissue with both dermatologic disease and non-diseased tissue from the same donor. Biopsies may also be taken for molecular and genetic analysis of specimen. Non-identifiable information regarding the patient, such as age, sex, race, cause of death, location, and description of diseased skin may be recorded.

Eligibility criteria: Inclusion Criteria:

* 16 years of age or older.
* willing to have a skin biopsy

Exclusion Criteria:

* under 16 years of age
* unable to carry out instructions

Primary outcomes:
measure: Factors in dermatologic diseases.
timeFrame: up to 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Irvine
country: United States
facility: Beckman Laser Institute and Medical Clinic
state: California
city: Irvine
country: United States
facility: Dermatology Clinic at Gavin Herbert Eye Institute
state: California
Study officials:
affiliation: University of California, Irvine
name: Kristen Kelly, MD
role: PRINCIPAL_INVESTIGATOR
References: